Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.82 CAD | +0.52% | -0.68% | +12.14% |
Mar. 22 | Knight Therapeutics Price Target Raised to $7 at RBC | MT |
Mar. 21 | Knight Therapeutics Reports Fourth Quarter Results | MT |
Sales 2024 * | 345M 252M | Sales 2025 * | 354M 259M | Capitalization | 589M 431M |
---|---|---|---|---|---|
Net income 2024 * | 3M 2.2M | Net income 2025 * | 2M 1.46M | EV / Sales 2024 * | 1.71 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.66 x |
P/E ratio 2024 * |
64.3
x | P/E ratio 2025 * |
59.4
x | Employees | 725 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 53.56% |
Latest transcript on Knight Therapeutics Inc.
1 day | +0.52% | ||
1 week | -0.68% | ||
Current month | +9.81% | ||
1 month | +10.86% | ||
3 months | +7.18% | ||
6 months | +29.05% | ||
Current year | +12.14% |
Managers | Title | Age | Since |
---|---|---|---|
Samira Sakhia
CEO | Chief Executive Officer | 55 | 13-10-31 |
Jonathan Goodman
FOU | Founder | 56 | 13-10-31 |
Arvind Utchanah
DFI | Director of Finance/CFO | - | 16-06-19 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Gale
BRD | Director/Board Member | 74 | 14-01-05 |
Jonathan Goodman
FOU | Founder | 56 | 13-10-31 |
Robert N. Lande
BRD | Director/Board Member | 61 | 12-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.19% | 11 M€ | -.--% | ||
0.01% | 773 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-22 | 5.79 | +1.22% | 40,198 |
24-04-19 | 5.72 | -1.21% | 22,247 |
24-04-18 | 5.79 | -1.19% | 75,589 |
24-04-17 | 5.86 | +1.56% | 59,023 |
24-04-16 | 5.77 | +0.17% | 56,114 |
Delayed Quote Toronto S.E., April 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.14% | 427M | |
+12.00% | 9.18B | |
-16.33% | 4.78B | |
+6.40% | 3.87B | |
+26.98% | 3.73B | |
+28.27% | 2.52B | |
-26.55% | 2.27B | |
-25.02% | 2.21B | |
+5.82% | 1.95B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- GUD Stock